Ambulatory glucose profile (AGP): development of a common, web-based application to record and report continuous glucose monitoring data

Rs, Mazze; Strock, Ellie S.; Cuddihy, Robert; Wesley, David

doi:10.1016/s1499-2671(09)33083-x

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of the AGP and of related forms of analysis implicitly requires stability and reproducibility of glucose patterns from day to day. [31][32][33][34] If glucose patterns are erratic, one may not be able to conclude anything other than the fact that the patterns are erratic. By widening the size of the time window used for retrospective analysis to 1, 2, or 4 weeks to construct an AGP, one is able to take advantage of signal averaging: random noise will tend to cancel out, revealing the underlying pattern.…”

Section: Instability Of Patterns and Reproducibility To Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities

Rodbard¹

2016

Diabetes Technology & Therapeutics

539

451

View full text Add to dashboard Cite

Continuous glucose monitoring (CGM) provides information unattainable by intermittent capillary blood glucose, including instantaneous real-time display of glucose level and rate of change of glucose, alerts and alarms for actual or impending hypo- and hyperglycemia, "24/7" coverage, and the ability to characterize glycemic variability. Progressively more accurate and precise, reasonably unobtrusive, small, comfortable, user-friendly devices connect to the Internet to share information and are sine qua non for a closed-loop artificial pancreas. CGM can inform, educate, motivate, and alert people with diabetes. CGM is medically indicated for patients with frequent, severe, or nocturnal hypoglycemia, especially in the presence of hypoglycemia unawareness. Surprisingly, despite tremendous advances, utilization of CGM has remained fairly limited to date. Barriers to use have included the following: (1) lack of Food and Drug Administration approval, to date, for insulin dosing ("nonadjuvant use") in the United States and for use in hospital and intensive care unit settings; (2) cost and variable reimbursement; (3) need for recalibrations; (4) periodic replacement of sensors; (5) day-to-day variability in glycemic patterns, which can limit the predictability of findings based on retrospective, masked "professional" use; (6) time, implicit costs, and inconvenience for uploading of data for retrospective analysis; (7) lack of fair and reasonable reimbursement for physician time; (8) inexperience and lack of training of physicians and other healthcare professionals regarding interpretation of CGM results; (9) lack of standardization of software methods for analysis of CGM data; and (10) need for professional medical organizations to develop and disseminate additional clinical practice guidelines regarding the role of CGM. Ongoing advances in technology and clinical research have addressed several of these barriers. Use of CGM in conjunction with an insulin pump with automated suspension of insulin infusion in response to actual observed or predicted hypoglycemia, as well as progressive refinement of closed-loop systems, is expected to dramatically enhance the clinical utility and utilization of CGM.

show abstract

Section: Instability Of Patterns and Reproducibility To Resultsmentioning

confidence: 99%

“…A panel sponsored by the T1D Exchange recommended that a standardized method, the Ambulatory Glucose Profile (AGP), [31][32][33][34] be used to analyze and display retrospective data. This AGP display is currently generated by the FGM system and should be applicable to all CGM systems.…”

Section: Introductionmentioning

confidence: 99%

Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities

Rodbard¹

2016

Diabetes Technology & Therapeutics

539

451

View full text Add to dashboard Cite

show abstract

“…Since 1987, there have been several attempts to standardize glucose data reporting. [20][21][22][23][24][25] The Helmsley Charitable Trust organized a meeting that included experts in the field of diabetes, members of various diabetes organizations, diabetes device industry representatives, and Food and Drug Administration (FDA) members. 26 A consensus statement for the standardization of CGM metrics and guidance for clinicians and researchers on the reporting of CGM data, also known as the ambulatory glucose profile (AGP), was published, which is now adopted by many CGM manufacturers.…”

Section: Introductionmentioning

confidence: 99%

Standardized Hybrid Closed-Loop System Reporting

Shah

Garg

2021

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

“…These situations can often be seen in our society. But, such negligence is considered quite dangerous and may further cause several health disorders, sometimes leading to death (Heinemann and Freckmann, 2015; Mazze et al , 1987, 2008, 2009).…”

Section: Introductionmentioning

confidence: 99%

Continuous glucose monitoring: a systematic review of sensor systems and prospects

Ray

2018

View full text Add to dashboard Cite

Purpose Continuous glucose monitoring (CGM) is a notable invention introduced in the biomedical industry. It provides valuable information about intermittent capillary blood glucose that is normally unattainable by regular clinical blood sample tests. CGM includes several progressive facilities such as instantaneous and real-time display of blood glucose level, “24/7” coverage, continuous motion of alerts for actual or impending hypo- and hyperglycemia and the ability to characterize glycemic variability. CGM allows users and physicians to visualize and diagnose more accurate and precise rate of change of glucose by capacitating small, comfortable, user-friendly sensor devices. Sometimes, this vital information is shared to the personal message box over Internet. In short, CGM is capable to inform, educate, motivate and alert (IEMA) people with diabetes. Despite the huge expectation with CGM, the available solutions have not attracted much attention among people. The huge potential of CGM in future diabetic study relies on the successful implication of the CGM. This paper aims at disseminating of state-of-the-art knowledge about existing work around the CGM. Design/methodology/approach This paper presents a comprehensive systematic review on the recent developments in CGM development techniques that have been reported in credible sources, namely PubMed, IEEE Xplore, Science Direct, Springer Link, Scopus and Google Scholar. Detailed analysis and systematic comparison are provided to highlight the achievement and future direction of CGM deployment. Findings Several key challenges are also portrayed for suitable opportunistic orientation. CGM solutions from four leading manufacturers such as Tandem, Dexcom, Abbott and Medtronic are compared based on the following factors including accuracy (% MARD); sensor lifetime, calibration requirement, smart device, compatibility and remote monitoring. Qualitative and quantitative analyses are performed. Originality/value This work can be a valuable source of reference and guidance for future research in this field.

show abstract

Ambulatory glucose profile (AGP): development of a common, web-based application to record and report continuous glucose monitoring data

Cited by 5 publications

References 0 publications

Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities

Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities

Standardized Hybrid Closed-Loop System Reporting

Continuous glucose monitoring: a systematic review of sensor systems and prospects

Contact Info

Product

Resources

About